Prostate cancer drug gets Fast Track designation
Free newsletter via e-mail
Tools
The FDA has awarded Fast Track designation to Dendreon for its prostate cancer drug Provenge. Results from the phase III study show that Provenge could improve the survival rates of men with asymptomatic, metastatic, androgen-independent prostate cancer. Each year prostate cancer kills over 30,000 men.
- read this press release for more
More stories about Phase III FDA Dendreon Provenge Prostate Cancer Cancer Drugs Fast Track designation
SHARE
WITH: